Other

Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V.

Nxstage Medical, Inc.

Solvamed Gmbh

Teraklin Aktiengessellschaft

Margraf, Stefan

Jan Stange

Steffen Mitzner

Sebastian Klammt

Emil Reisinger

Dennis M Treu

William K Weigel

Joseph E Turk, Jr

Jens Altrichter

Stefan Margraf

Jan Loock

Dieter G Weiss

Gunter W Gross

Alexandra Gramowski

Dietmar Schiffmann

Jens Freytag

Wolfgang Ramlow

A method for determining an amount of functional albumin includes providing a test sample containing a defined amount of albumin of unknown binding capacity and a reference sample containing the same defined amount of albumin having a reference binding capacity, incubating the test and reference samples with a defined amount of at least one albumin-binding marker M under conditions that allow formation of complexes of the at least one albumin-binding marker M and albumin (M:A), removing the complexes, detecting a presence or an amount of unbound marker M in the samples after removal of the complex (M:A) through a first and a second test strips that allow for a determination of an amount of unbound marker M, and determining the amount of functional albumin based on the presence or the amount detected of marker M.

Methods for determining amount of functional albumin

Determining the relative binding capacity of albumin (A), and amount of functional albumin, involves at least two measurement solutions of a test and reference sample. The measurement solutions contain an albumin-binding marker M. The marker in the measurement solution of the test and reference samples exceeds the presumed available albumin binding capacity. The test sample contains a defined amount of albumin of unknown binding capacity. The reference sample contains the same defined amount of albumin having a reference binding capacity. The measurement solutions are incubated under conditions that allow M:A complexes to form. The M:A complexes are removed. The presence or amount of unbound marker M in the solutions is detected after M:A complex removal by a test strip that allows determination of the unbound marker. The relative binding capacity of albumin in the test sample based on the presence or detected amounts of unbound marker is determined.

Methods for determining the relative binding capacity of albumin

Methods, systems, and devices are disclosed, embodiments of which provide single pass dialysis to remove water and uremic toxins is performed simultaneously with the albumin dialysis therapy by passing the albumin solution through a dialysis filter which dialyses it before the solution is returned to the cycler. In embodiments, the single pass dialysis stage is upstream of the albumin filtering stage.

Single pass dialysis combined with multiple pass albumin dialysis

The invention relates to means and methods for the disinfection of an insertion channel to prevent in particular catheter sepsis, which significantly reduces the carry-over of germs even out of deeper skin layers by means of medical instruments, such as catheters, to be introduced into non-natural openings and also permits the decontamination of perioperatively contaminated medical instruments. The disinfection of the insertion channel is achieved by means of a method for the perioperative coating of a medical instrument to be inserted into an invasively produced bodily opening before use, comprising the application of a preferably viscous or foam-like composition containing at least one anti-infective compound, preferably a gel having octenidine, by means of an applicator, such that when said gel is used, the composition is also specifically effective in the first millimeters of the insertion channel. Furthermore, an immediate disinfecting action is provided over the entire coated surface.

Method and applicator for the perioperative disinfection of medical instruments to be inserted through non-natural openings

The invention relates to a method for the extra-corporeal qualitative and/or quantitative recording of neuro-toxic substances in the blood plasma of an individual. According to said method, a system containing neurones or neuronal networks, which have been cultivated on or applied to a micro-electrode array or a neuro-chip, in addition to a device for measuring the electrical activity of at least one or several of said neurones are provided, the neurones are brought into contact with a prepared sample of plasma and the electrical activity of the neurones is measured. The aim of the invention is to develop and improve said method in such a way that it supplies reliable, reproducible results for the recording of neuro-toxic substances in the blood plasma of an individual, in particular in the case of encephalopathic conditions, such as for example hepatic failure, or of coma conditions of various origins. To achieve this, prior to measurement, the blood plasma of an individual is prepared by being subjected to a filtration method, preferably an ultra-filtration method, whereby an exclusion limit, which causes the most extensive separation possible of the plasma protein from the other dissolved substances is selected, and/or prior to measurement, the blood plasma of an individual is prepared by being subjected to an extraction of liposoluble substances, using a solvent for liposoluble substances, and the ultra-filtrate or the extract containing the liposoluble substances, or both are used in succession or are blended together for the measurement.

Method for the extra-corporeal qualitative and/or quantitative recording of neurotoxic substances in the blood plasma of an individual

A process and set-up of therapeutic immunomodulation is provided for medicine. Many illnesses (i.e. Sepsis) are, among other things, characterized by a disruption of the immune system. In spite of previous therapies using antibiotics, the mortality rate is still very high. The administration of individual cytokins has not yet resulted in any convincing results. The use of cells in an extra-corporal circulation that can adsorb or self-release immunomodulatory effect substances is a completely new type of complex therapeutic approach to such illnesses, which leads to an improvement in the health of the affected patients.

Method for therapeutic immunmodulation of plasma

The present invention provides a process of separating substances bound to a first protein in a first liquid by means of a membrane separating the first liquid from a second liquid, the process comprising the steps of: a) impregnating the membrane by passing along the membrane a solution comprising a first acceptor protein having an acceptor function for the substances to be separated; b) dialyzing the first liquid against the second liquid, the second liquid comprising a second acceptor protein having an acceptor function for the substances to be separated, wherein the membrane separating the first and second liquids contains tunnel-like structures that permit passage of the substances to be separated to the second liquid but exclude passage of the first protein and the second acceptor protein.

Method for the separation of protein-bound substances from a

Growing community of inventors

Rostock, Germany

Jan Stange